The direct costs of multiple sclerosis-study in the Czech Republic

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F18%3A10384939" target="_blank" >RIV/00216208:11150/18:10384939 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/18:10384939 RIV/62690094:18450/18:50014697

Výsledek na webu

<a href="https://doi.org/10.1007/s10072-018-3551-7" target="_blank" >https://doi.org/10.1007/s10072-018-3551-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10072-018-3551-7" target="_blank" >10.1007/s10072-018-3551-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The direct costs of multiple sclerosis-study in the Czech Republic

Popis výsledku v původním jazyce

BackgroundMultiple sclerosis (MS) is a progressive autoimmune disease of the central nervous system that is often disabling and for which there is currently no cure, though disease-modifying treatment is now available. The aim of this study is to describe the current values of the direct costs of multiple sclerosis (MS) in the Czech Republic.MethodsAttention is focused on direct medical costs. The costs were monitored in the Czech Republic among 5673 patients in the period between 2011 and 2015. These costs included complex, special and targeted visits at the neurologist, blood collection and the costs of hospitalisation. The results refer to the diagnoses according to the International Statistical Classification of Diseases and Related Health Problems. The attention is focused on MS G35 (NS; brain stem; spinal cord; disseminated; generalised).ResultsThe average total direct costs per patient per year are 4838.1 Euro. Not every patient has to be hospitalised during the year, and not every patient has prescribed medication. According to the above data, 12% of patients are hospitalised and 55% of patients are prescribed medication. The minimum average cost per patient without medication and hospitalisation is 54.1 Euro.ConclusionCost evaluation across countries is difficult due to the different evidence. If only selected direct costs considered in this study are compared, the absolute economics burden increases over time. The only statistically significant difference in the average price and the time spent is between 2012 and 2013, where the correlation value is 0.597.

Název v anglickém jazyce

The direct costs of multiple sclerosis-study in the Czech Republic

Popis výsledku anglicky

BackgroundMultiple sclerosis (MS) is a progressive autoimmune disease of the central nervous system that is often disabling and for which there is currently no cure, though disease-modifying treatment is now available. The aim of this study is to describe the current values of the direct costs of multiple sclerosis (MS) in the Czech Republic.MethodsAttention is focused on direct medical costs. The costs were monitored in the Czech Republic among 5673 patients in the period between 2011 and 2015. These costs included complex, special and targeted visits at the neurologist, blood collection and the costs of hospitalisation. The results refer to the diagnoses according to the International Statistical Classification of Diseases and Related Health Problems. The attention is focused on MS G35 (NS; brain stem; spinal cord; disseminated; generalised).ResultsThe average total direct costs per patient per year are 4838.1 Euro. Not every patient has to be hospitalised during the year, and not every patient has prescribed medication. According to the above data, 12% of patients are hospitalised and 55% of patients are prescribed medication. The minimum average cost per patient without medication and hospitalisation is 54.1 Euro.ConclusionCost evaluation across countries is difficult due to the different evidence. If only selected direct costs considered in this study are compared, the absolute economics burden increases over time. The only statistically significant difference in the average price and the time spent is between 2012 and 2013, where the correlation value is 0.597.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neurological Sciences

ISSN

1590-1874

e-ISSN

—

Svazek periodika

39

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

7

Strana od-do

2115-2121

Kód UT WoS článku

000452518300012

EID výsledku v databázi Scopus

2-s2.0-85053373870